USA
News & Media
Take a closer look at what we’re doing across Teva worldwide
Press releases
Sep 3 / 2019
Teva Announces United States Department of Commerce Appointment of Brendan O’Grady to Investment Advisory Council
Sep 3 / 2019
Teva to Present New Analyses of Fremanezumab Efficacy and Safety in Adult Patients with Difficult-to-Treat Migraine at 19th Congress of the International Headache Society
Late breaking data examines 10-year cost effectiveness of fremanezumab, while one oral presentation and 29 posters highlight FOCUS Phase IIIb study data in adult patients with migraine and documented inadequate response to 2-4 classes of prior preventive treatments, along with patient survey results and post hoc efficacy results following the 1-year Phase III HALO long-term study
Aug 23 / 2019
Notice to Healthcare Professional Regarding Safety Information That May Be Absent in the Package Insert for HYDROMORPHONE HYDROCHLORIDE
Aug 21 / 2019
Fremanezumab Data in The Lancet Demonstrate Clinically Meaningful Reduction in Monthly Migraine Days Versus Placebo for Patients with Difficult-To-Treat Migraine
The FOCUS study looked at patients who previously experienced inadequate response to two to four migraine preventive medication classes. Treatment with fremanezumab was shown to be effective versus placebo.
Top Stories
Read the latest Teva news
18 Jul 2019
Meet the Expert: Corey Sparks
Corey Sparks, VP of Finance and Controller of North America talks about what it's like to work at Teva.
11 Jul 2019
Social Impact at Teva—2018 Progress and More: A Conversation with Amalia Adler-Waxman
Social Impact at Teva—2018 Progress and More: A Conversation with Amalia Adler-Waxman, Vice President, Social Impact & Responsibility.
21 Jun 2019
Celebrating Pride Month At Teva
Teva’s Pride Employee Resource (ERG) group members reflect on the role the Stonewall Uprising played in their own lives and the important mission of the ERG for fostering a culture of inclusion.
